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• Renal cell carcinoma, unclassified (RCC-U) is a diagnosis of exclusion. 
• RCC-U is a morphologically and immunophenotypically heterogenous group of tumors. 





Renal cell carcinoma, unclassified (RCC-U), is a heterogenous group of tumors that do not fit in 
any recognized histologic types. Immunohistochemical studies are frequently used to 
characterize these tumors. Herein, we sought to investigate the immunophenotypes of 300 cases 
of RCC-U. The cases were morphologically classified into three groups: 
oncocytoma/chromophobe renal cell carcinoma-like –Group 1; clear cell renal cell carcinoma-
like – Group 2; and others (i.e., papillary renal cell carcinoma-like/collecting duct-like/pure 
sarcomatoid) – Group 3. Male-to-female ratio was 1.4. Most cases (168, 66%) were Group 1. 
Group 3 was associated with larger tumor size, advanced stage, and frequent lymph node 
metastases. The most commonly used immunohistochemical stains were CK7 (n=270; 89.5%), 
vimentin (n=186, 82%), CD10 (n=181; 59.9%), and AMACR (n=162; 54%). Pancytokeratin 
(79/101; 78.2%) and PAX8 (54/61; 88.5%) were diffusely positive in most cases, followed by 
AMACR (69/117; 59%). CD117 was positive in 53/118 cases (45%). RCC-U is a 
morphologically and immunophenotypically heterogenous group of tumors, comprehensive 






The latest edition of the World Health Organization (WHO) classification on primary 
renal epithelial neoplasms include fourteen recognized and four provisional renal cell carcinoma 
(RCC) subtypes (1,2).  Failure to classify an RCC, however, is not uncommon, seen in up to 
5.7% of all RCCs, and “renal cell carcinoma, unclassified (RCC-U)” designation is used for such 
tumors (3). In the 2016 WHO classification system, “renal cell carcinoma, unclassified (RCC-
U)” designation is used for tumors that do not fit in any recognized histologic types (4). These 
tumors include those with a combination of features of more than one recognized subtype, with 
mucin production, or with unrecognized epithelial cell subtypes; low or high grade unclassified 
oncocytic neoplasms (4). RCC-U may have pure sarcomatoid morphology with unrecognized 
epithelial cell type or without an identifiable epithelial component (4).  In a recent study, Perrino 
and colleagues further subclassified RCC-U into three morphological subgroups based on 
predominant morphological features: oncocytoma/chromophobe RCC-like – Group 1; clear cell 
RCC-like – Group 2; and others (i.e., papillary RCC-like/collecting duct-like/pure sarcomatoid) 
– Group 3 (5). 
RCC-U is a heterogenous group of tumors with different cytology, genetics, 
microenvironment, growth pattern and metastatic potential. Its clinical outcome is variable, and 
is mainly determined by histologic grade and pathologic stage (5). Ancillary studies are virtually 
always employed in the diagnostic work-up of RCC-U, and immunohistochemistry (IHC) is the 
most utilized tool. Practical recommendations from various genitourinary pathology experts on 
the use of IHC are targeted in light of whether the tumor is predominantly eosinophilic (6-9) , 
clear cell (7-10), or low- or high- grade cytology (6,7) or different growth patterns (7,9); 
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however, immune-profile of RCC-U has not been systematically evaluated. Herein, we sought to 
investigate the immunophenotypes of RCC-U in this largest series reported to date.  
 
Materials and Methods 
Three hundred cases diagnosed as RCC-U at the Indiana University between 2006-2019 
were analyzed. The RCC-U cases (n=130) reported by Perrino et al (5) were also included. 
Available hematoxylin and eosin stained slides and immunohistochemical (IHC) studies were 
reviewed by the authors (MA and LC) using the 2016 WHO classification criteria (4). Type of 
the procedure (partial/total nephrectomy or biopsy), gender, age at diagnosis, cytomorphological 
features, tumor grade and pathologic stage were recorded (11-13). As previously described by 
Perrino et al (5), the cases were classified into three groups based on their predominant 
morphologic feature: oncocytoma/chromophobe RCC-like –Group 1; clear cell RCC-like – 
Group 2; and others (i.e., papillary RCC-like/collecting duct-like/pure sarcomatoid) – Group 3. 
The predominant morphological features of each case were designated after review the slides by 
the authors (MA and LC). 
Seventeen of the most used biomarkers for each case, when applicable, were recorded. 
These antibodies included AE1/AE3 (AE1/AE3 clone, ready-to-use [RTU], Dako), carbonic 
anhydrase IX (CAIX; MRQ-54 clone, 1:200, Cell Marque), cathepsin K (3F9 clone, 1:100, 
Abcam), CD10 (56C6 clone, RTU, Dako), cytokeratin 7 (CK7; OV-TL 12/30, Dako), CK20 
(Ks20.8 clone, RTU, Dako), CD117 (YR145 clone, RTU, Cell Marque), epithelial membrane 
antigen (EMA; E29 clone, RTU, Dako), fumarate hydratase (FH; J-13 clone, 1:200, Santa Cruz), 
HMB45 (HMB45, RTU, Dako), melan A (A103 clone, RTU, Dako), P504S (13H4 clone, RTU, 
Dako), PAX8 (MRQ-50 clone, 1:100, Cell Marque), succinate dehydrogenase B (SDHB; 
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21A11AE7 clone, 1:500, Abcam), TFE3 (MRQ-37, 354R-18 clone, 1:100, Cell Marque), and 
vimentin (V9 clone, RTU, Dako). The special stain, colloidal iron, was interpreted as “atypical” 
where there was expression in unexpected areas of the tumor cells, such as luminal-only staining. 
This research was approved by the Institutional Review Board at Indiana University. 
Results 
A total of 300 cases were reviewed. The male-to-female ratio was 1.4 (179/121) and the 
patients ranged in age from 19–88 years (median, 61 years). Of these cases, 180 (60%) were 
from total nephrectomies, 118 (39%) from partial nephrectomies, and 2 from renal core needle 
biopsies. Most of the RCC-U cases (168, 66%) were Group 1, whereas Groups 2 and 3 had 52 
(17%) and 50 (16%) cases, respectively (Figure 1A-1H). Median tumor size was 5.0 cm (1–24.9 
cm). World Health Organization/International Society of Urologic Pathology (WHO/ISUP) 
nuclear grade 3 was the most common (137, 46%), followed by grade 2 (96, 32%), and grade 4 
(57, 19%). Sarcomatoid features were seen in 19 cases, most of which were in Group 3 
(accounting for 20% of all cases in this group). Most of the cases in Groups 1 and 2 were organ 
confined (70% and 54%, respectively). In contrast, 62% of cases in Group 3 had at least pT3 
disease. Most cases did not have information about lymph node status, although 55% (12/22) of 
the cases with known lymph node status in Group 3 had at least one metastatic lymph node. 
(Table 1).  
Overall biomarker profile for each group is illustrated in Tables 2 and 3 and Figure 2. 
The most commonly used immunohistochemical stains were CK7 (n=270; 89.5%), vimentin 
(n=186, 82%), CD10 (n=181; 59.9%), and AMACR (n=162; 54%). Pancytokeratin (79/101; 
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78.2%) and PAX8 (54/67; 88.5%) were diffusely positive in most cases, followed by AMACR 
(69/117; 59%). CD117 was positive in substantial amount of cases (53/118; 45%). Colloidal iron 
was diffusely positive in (24/107; 22%), although atypical expression was not uncommon 
(20/107;18%).  
In group 1 RCC-U, CK7 was positive in majority of cases (109/183; 59%), focal 
expression (57/109;52%) was as common as diffuse expression (52/109;48%) (Figure 2, Table 
2). Approximately half of the cases in group 1 RCC-U (50/99;51%) had CD117 expression, in a 
predominantly diffuse (40/50;80%) pattern. AMACR expression was seen in majority of group 1 
cases (47/72; 65%). Colloidal iron staining was observed in many cases in this group (43/99;43% 
of cases), roughly in half of the cases the staining pattern was atypical (20/43;46%). In group 2 
(Figure 2c), most tumors had CAIX (30/37; 81%), 28 diffuse), CD10 (38/41; 92%), and 
AMACR (27/34; 79%) with mostly diffuse pattern (CAIX 28/30; 93%, CD10 32/38; 84%, 
AMACR 24/27;88%). CK7 was also positive in more than half of the cases (24/46 52%),  mostly 
frequently with diffuse pattern (15/24;62%). Similarly, the majority of tumors in group 3 RCC-U 
(Figure 2d) had CAIX (11/22 77%), CD10 (24/29 82%), and AMACR (28/32 87%) expressions 
with mostly diffuse pattern (CAIX 11/11; 100%, CD10 18/24; 66%, AMACR 24/28; 86%). Few 
cases in group 3 had CK7 expression (15/41; 36%) with mainly focal expression (9/15; 60%). 
(Figure 2, Table 2). 
TFE3 was expressed by immunohistochemistry in few cases (9/102; 8%) (Figure 3a), 
although all cases had subsequent negative TFE3 findings by fluorescence in situ hybridization. 
Sixteen cases (~5%) had features of “low-grade oncocytic tumor” including bland eosinophilic 
nuclei, areas of small distinct and confluent tumor clusters, and diffuse CK7 expression with 
negative CD117 (Figure 3b). Three of 198 (~2%) eosinophilic tumors had high nuclear grade, 
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intermixed clear cells with intracytoplasmic vacuoles, and diffuse cathepsin K expression, 
consistent with “high-grade oncocytic tumor” (Figure 3c). In Group 1, five cases had CK20 
expression, although these tumors did not have morphologic evidence of eosinophilic solid and 
cystic RCC (Figure 3d). 
 
Discussion 
The current cohort of three hundred cases of unclassified renal cell carcinoma (RCC-U), 
to the best of our knowledge, is the largest series ever reported in the English literature. One of 
our main goals is to document epidemiologic characteristics of the patients, histologic grade and 
staging information of these tumors, as well as analyzing the immunohistochemical 
characteristics of each morphological subgroups. This report of comprehensive immunoprofiles 
of the largest RCC-U series may serve as a main reference for future studies of this uncommon 
disease. 
Many RCC subtypes share multiple overlapping morphologic and immunophenotypic 
features (Figures 4 and 5), and a panel of biomarkers are often required to finalize diagnostic 
workup (2,7,9,14-16). Diverse morphological manifestations of RCC-U have been observed in 
current and previous RCC studies (3,5,17-24) The majority of RCC-U with eosinophilic 
morphology (Group 1) had less advanced disease when compared to RCC-U with high-grade 
features (Group 3). Eosinophilic renal tumors pose a diagnostic challenge because oncocytoma, a 
benign neoplasm, is in the differential. The most commonly used immunohistochemical markers 
for oncocytoma are reported to be CK7 (94%), CD117 (71%), and vimentin (65%), as well as the 
special stain, colloidal iron (59%) (25); these are also the most common biomarkers (and special 
stain) in the diagnostic workup of Group 1 RCC-U in our study (Figure 2, Table 3).  
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Clear cell histology is also commonly observed in RCC-U (designated Group 2 RCC-U, 
Table 3) (5). The majority of group 2 RCC-U cases had diffuse CAIX and CD10 expression, and 
AMACR expression was also present in 79% of cases. AMACR expression might be helpful in 
differentiating RCCU from clear cell renal cell carcinoma, as its expression is seen only up to 
25% of cases with usually focal pattern (7,9). Prominent morphologic variation, including true 
papillary growth, was present in these tumors. Important differential diagnostic considerations 
include clear cell papillary RCC and MIT-family translocation associated RCC (MIT-RCC) 
(Figure 4) (14). 
Group 3 RCC-U includes tumors with predominantly papillary RCC-like or collecting 
duct-like phenotype and tumors with pure sarcomatoid morphology (5). Group 3 RCC-U was 
associated with larger tumor size, advanced stage, and frequent lymph node metastases. 
Diagnosis of RCC with poorly differentiated morphologic features should start with ruling out 
tumors of urothelial or secondary origin (14). Clinical history and expression profile of 
SMARCB1 and OCT4 may help identify renal medullary carcinoma (loss of SMARCB1/positive 
OCT4) and collecting duct carcinoma (retained SMARCB1/negative OCT4) (7). dFH-RCC 
should also be in the differential as the characteristic prominent inclusion-like nucleoli may not 
be readily seen. ALK-RCC have high-grade morphology that is similar to renal medullary 
carcinoma with no history of hemoglobinopathy, and is rare––like these two entities––as only 
2/88 RCC were found to have ALK-IHC expression (26). Pure sarcomatoid morphology is now 
considered one of the definitions of RCC-U (4), therefore adequate sampling of the tumor is 
required (19). 
In summary, RCC-U constitutes a group of distinct renal neoplasms with substantial 
immunophenotypic and morphologic heterogeneity. RCC-U, by its nature, is a diagnosis of 
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exclusion and efforts in identifying certain immunoprofile specific for RCC-U cases are fraught 
with difficulties. Nonetheless, interpreting the immunoprofile in light of the morphologic 
subgroups may help in distinguishing RCC-U from recognized entities.  The diagnosis of RCC-U 
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Figure 1. Morphologic and immunohistochemical staining features of selected cases in each 
group. Group 1 RCC-U are cases with oncocytoma/chromophobe RCC-like morphology, 
although many features corresponding to more than one entity can be seen with abrupt changes. 
Psammoma bodies (arrow) are also not specific to any renal tumors (A, 40x). This eosinophilic 
neoplasm shows complete loss of CK7 expression (B, 100x) with internal positive control of 
normal renal tubules. Atypical colloidal iron staining (C, 200x) is seen where smaller 
eosinophilic tumor cells have strong membranous/cytoplasmic staining, whereas larger cells are 
negative. Group 2 RCC-U may have morphologic features that are acceptable to clear cell RCC 
(D, 100x), although in this case CAIX expression is completely lost (E, 100x), with oncocytoma-
like CK7 expression (F, 100x). Group 3 RCC-U are usually high grade (G, 100x), therefore 
PAX8 (H, 100x) and p63 (I, 100x) expressions should be evaluated to determine the renal origin. 
 
Figure 2. Summary of immunohistochemical stains performed in all cases (A), in Group 1 (B), 
in Group 2 (C), and in Group 3 (D). 
 
Figure 3. RCC-U cases resembling recognized or emerging entities. An eosinophilic tumor with 
high-grade nuclear features and solid to packed tubular growth pattern (A, 100x) shows diffuse 
and strong TFE3 expression (B, 100x), although AE1/AE3 is strongly expressed (C, 100x) and 
TFE3-FISH was negative in this case. Some eosinophilic RCC-U (D, 100x) have focal CK20 
expression (E, 100x), with CK7 absence (F, 100x) resembling eosinophilic solid and cystic 
RCC, although morphologic features, such as cystic growth or coarse intracytoplasmic granules, 
are absent. A recently identified entity, low-grade oncocytic tumor, has nuclear features similar 
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to oncocytoma with solid growth pattern with abrupt edematous changes in the stroma and fused 
tumor nests of varying size (G, 100x). Contrary to oncocytoma, these tumors are characterized 
by diffuse CK7 expression (H, 100x) and negative CD117 (I). Finally, high-grade oncocytic 
tumors (J, 100x) have diffuse cathepsin K expression (K, 100x), no loss of pancytokeratin (L, 
100x), and negative TFE3 expression (not shown). 
Figure 4. Immunophenotypic and morphologic heterogeneity of RCC. With an increasing 
number of new entities, diagnosing renal cell neoplasms is challenging. Several morphologic 
features, including cytoplasmic features, growth pattern, and nuclear features, should be taken 
into account, although many entities have overlapping features. Abbreviations: ACKD-RCC = 
acquired cystic kidney disease-associated renal cell carcinoma, ALK-RCC = anaplastic 
lymphoma kinase-associated renal cell carcinoma, AMLEC = angiomyolipoma with epithelial 
cysts, BSPRCC = biphasic solid and cystic renal cell carcinoma, CCRCC = clear cell renal cell 
carcinoma, CDC = collecting duct carcinoma, ChRCC = chromophobe renal cell carcinoma, 
dFHRCC = fumarate hydratase-deficient renal cell carcinoma, dSDH-RCC = succinate 
dehydrogenase-deficient renal cell carcinoma, eCCRCC = epithelioid clear cell renal cell 
carcinoma, eChRCC= epithelioid chromophobe renal cell carcinoma, ESC-RCC = eosinophilic 
solid and cystic renal cell carcinoma, HOT = high-grade oncocytic tumor, LOT = low-grade 
oncocytic tumor, MCRNLMP = multilocular clear cell renal neoplasm with low malignant 
potential, MIT-RCC = MIT-family translocation associated renal cell carcinoma, MTSCC = 
mucinous tubular and spindle cell carcinoma, PA = papillary adenoma, PRCC = papillary renal 
cell carcinoma, RAT = renal cell carcinoma with angioleiomyomatous stroma, RMC = renal 
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medullary carcinoma, TcRCC = tubulocystic renal cell carcinoma, TFRCC = thyroid follicle like 
renal cell carcinoma. 
Figure 5: After determining that the tumor cells are predominantly eosinophilic (A), clear (B), or 
with high-grade features (C), immunohistochemistry should be performed if morphologic 
evaluation is insufficient for diagnosis. Despite classical definition, MIT-RCC can have many 
different growth patterns. Color codes on different entities match with the color of prominent 
growth pattern. Abbreviations: ACKD-RCC = acquired cystic kidney disease-associated renal 
cell carcinoma, ALK-RCC = anaplastic lymphoma kinase-associated renal cell carcinoma, 
AMLEC = angiomyolipoma with epithelial cysts, BSPRCC = biphasic solid and cystic renal cell 
carcinoma, CCRCC = clear cell renal cell carcinoma, CDC = collecting duct carcinoma, ChRCC 
= chromophobe renal cell carcinoma, dFHRCC = fumarate hydratase-deficient renal cell 
carcinoma, dSDH-RCC = succinate dehydrogenase-deficient renal cell carcinoma, eCCRCC = 
epithelioid clear cell renal cell carcinoma, eChRCC= epithelioid chromophobe renal cell 
carcinoma, ESC-RCC = eosinophilic solid and cystic renal cell carcinoma, HOT = high-grade 
oncocytic tumor, LOT = low-grade oncocytic tumor, MCRNLMP = multilocular clear cell renal 
neoplasm with low malignant potential, MIT-RCC = MIT-family translocation associated renal 
cell carcinoma, MTSCC = mucinous tubular and spindle cell carcinoma, PA = papillary 
adenoma, PRCC = papillary renal cell carcinoma, RAT = renal cell carcinoma with 
angioleiomyomatous stroma, RMC = renal medullary carcinoma, TcRCC = tubulocystic renal 
cell carcinoma, TFRCC = thyroid follicle like renal cell carcinoma.
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Table 1. Characteristic features of the study cohort. 
 
All categories Oncocytoma/ChRCC-like Clear cell RCC-like PRCC-like/CDC-like/pure sarcomatoid 
Total case (%) 300 (100%) 198 (66%) 52 (18%) 50 (16%) 
Median age (range) 61 (19 -88) 62 (19-88) 59 (33 – 85) 
 
Male/female (ratio) 179/121 (1.4) 116/82 (1.4) 30/22 (1.3) 
 
Procedure 
   
 
Radical nephrectomy 180 (60%) 106 (54%) 32 (62) 42 (84%) 
Partial nephrectomy 118 (39%) 90 (45%) 20 (38) 8 (16%) 
Biopsy 2 (1%) 2 (1%) 0 0 
Median tumor size (range) (cm) 5 (1-24.9) 4.5 (1-23.5) 4.8 (1.4-14.7) 6.5 (2-24.9) 
Nuclear grade (%) 
    
NA 10 (3%) 5 (2.5) 4 (8%) 1 (2%) 
1 0 0 0  0  
2 96 (32%) 77 (38%) 13 (25%) 6 (12%)  
3 137 (46%) 87 (44%) 27 (52%) 23 (46%) 
4 57 (19%) 29 (15%) 8 (15%) 20 (40%) 
Sarcomatoid component 19 (6%) 7 (4%) 2 (4%) 10 (20%) 
Tumor stage 
    
T1a 112 (38%) 83 (42%) 19 (37%) 10 (20%) 
18 
T1b 45 (15%) 32 (16%) 6 (12%) 7 (14%) 
T2a 12 (4%) 9 (5%) 2 (4%) 1 (2%) 
T2b 14 (5%) 11 (6%) 2 (4%) 1 (2%) 
T3a 98 (33%) 54 (27%) 23 (46%) 21 (42%) 
T3b 4 (1%) 2 (1%) 0 2 (4%) 
T3c 3 (1%) 1 (<1%) 0 2 (4%) 
T4 10 (3%) 4 (2%) 0 6 (12%) 
Lymph node status 
Not applicable 230 (77%) 158 (81%) 44 (85%) 28 (56%) 
N0 42 (14%) 26 (13%) 6 (12%) 10 (20%) 
N1 26 (9%) 12 (6%) 2 (4%) 12 (24%) 
Footnote: Staging is per American Joint Committee on Cancer cancer staging manual, 8th edition. CDC= collecting duct carcinoma; 
ChRCC = chromophobe renal cell carcinoma; PRCC = papillary renal cell carcinoma; RCC = renal cell carcinoma. 
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Table 2. Immunohistochemical summary of 300 renal cell carcinoma, unclassified cases. 
Pancytoker
atin 
PAX8 CAIX CD10 AMACR Vimentin CK7 CD117 
Colloidal 
iron 





112 77 110 181 162 186 270 118 107 102 90 93 72 15 44 45 10 
Diffuse 88 70 55 96 81 60 73 42 24 1 3 0 0 0 0 25 
Focal 14 4 11 38 21 28 75 11 22 8 2 3 0 0 0 7 
Negative 10 3 44 47 36 98 122 65 61 93 85 90 72 15 44 13 10 
Equivocal 3 
Atypical 20 
Footnote: Diffuse = expression in more than 50% of tumor cells; focal =expression in less than 50% of tumor cells; negative = no 





Table 3. Morphologic and Immunophenotypic differences in renal cell carcinoma, unclassified (RCCU) 




RCC-like (Group 1) 
Predominantly eosinophilic 
cytoplasm, nested and/or solid 
sheets with occasional papillae 
formation 
• 198/300 (66%) 
• Mostly organ confined (70%) 
• Relatively small (median 4.5 
cm),  
• Few ISUP/WHO grade 4 (15%) 
 
CK7 (59%), CD117 (50%), 
AMACR (65%), vimentin 
(39%), colloidal iron (43%) 
Group 2: 
Clear cell RCC-like  
Predominantly clear cytoplasm 
and delicate vasculature with 
occasional papillae formation 
• Majority organ confined (54%) 
• Few ISUP/WHO grade 4 (15%) 
 
 
CAIX (81%), CD10 (92%), 







Tumors with fine fibrovascular 
cores/tubulopapillary 
architecture and high nuclear 
grade 
 
• Large tumors (median 6.5 cm) 
• Advanced tumor stage (≥T3a 
62%),  
• ISUP/WHO grade 4 (40%) 
 
CAIX (77%), CD10 (82%), 
AMACR (87%), CK7 (36%) 





